Pro-Life Organization, AVM Biotechnology Receives Approval for Clinical Trials for New Cancer Treatment – Potential to Treat Covid-19

LifeSiteNews: Pro-Life Catholic Scholars: Coronavirus is Not the Work of An Angry ‘Mother Earth’
April 20, 2020
CNA: Pro-Life Leaders Call for Coronavirus Vaccine Without Abortion Ties
April 20, 2020

Children of God for Life, April 19, 2020

(Seattle) Sound Choice is pleased to announce AVM Biotechnology has received approval to start clinical trials for a promising new cancer treatment, AVM0703 is an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. Patients are being sought to begin Phase I/II trials.

AVM0703 works by supercharging and mobilizing immune cells. When a patient is treated with AVM0703 supercharged immune cells (natural killer T-cells, gamma delta T cells and dendritic cells) invade and destroy tumors more powerfully than untreated immune cells.

Because of its mechanism of action, AVM0703 is also a potential treatment for viruses like COVID-19.

Within 2-7 days after treatment a patient will know whether they have responded. Unlike chemotherapy and radiation, AVM0703 spares platelets and red blood cells, limiting the need for transfusions and lessening hospital stays. Chemotherapy and radiation toxicities are well-known. AVM0703 side-effects are temporary and medically managed.

This exciting new treatment is approved for human trials in treating Lymphoma, Mantel Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, Burkitt or Burkitt-like Lymphoma/Leukemia, Chronic and Small Lymphocytic Leukemias, and B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, acute leukemia/lymphoma, acute leukemias of ambiguous lineage, or natural killer (NK) cell lymphoblastic leukemia/lymphoma.

AVM Biotech was named one of the top 10 best Biotech and Pharma companies to keep your eye on in 2019 by Mirror Review Online Magazine. It’s founder and Managing Partner is Dr. Theresa Deisher, Ph.D. AVM0703 is a personal mission for Dr. Deisher as she lost her 14 year-old son to Burkitt’s Lymphoma, one of the conditions that AVM0703 can treat.

Inquiries can be sent to